58 results about "Sulfamide" patented technology

The invention discloses a low-temperature zinc ion battery high-entropy eutectic electrolyte and a preparation method and application thereof, and relates to the field of batteries, the electrolyte comprises a hydrogen bond donor, a hydrogen bond acceptor and a solvent; the hydrogen bond donor is at least one of methyl sulfonamide, thioformamide, butyramide, asparagine, tert-butylamine, dimethyl propane diamine, oxalyl diamine, benzamide, sulfamide and ethyl sulfonamide; the hydrogen bond receptor is at least one of aspartic acid, glutamic acid, methionine, zinc chloride, zinc perchlorate, zinc fluoborate and zinc acetate; the preparation method comprises the following steps: mixing a hydrogen bond donor and a hydrogen bond acceptor, and heating to convert a solid into a liquid phase; and adding a solvent, and uniformly mixing to obtain the product. The invention also provides a zinc ion battery containing the electrolyte. The high-entropy eutectic electrolyte has the beneficial effects that-NH2 and halogen or carboxyl form hydrogen bonds to perform eutectic reaction, the freezing point of the eutectic solution is lower than that of a reactant, and the solvent is added to improve the confusion degree of the electrolyte, so that the high-entropy eutectic electrolyte is prepared.

The invention provides a sodium ion battery without a negative electrode, which adopts sodium ferric phosphate as a positive electrode active material and does not contain a negative electrode active material. According to the negative-electrode-free sodium ion battery, the electrochemical performance, the cycling stability and the safety of the battery are remarkably improved, and the conductivity and the charge transmission efficiency of the positive electrode material are improved. The surface of the negative electrode current collector is roughened, so that the surface area and active sites are increased, and the deposition efficiency and stability of sodium ions are improved. Additives such as sulfamide-grafted nano-diamond are added into the electrolyte, so that the conductivity and the electrochemical stability of the electrolyte are optimized. Meanwhile, by adjusting the concentration of the sodium hexafluorophosphate sodium salt electrolyte, the proportion of the cyclic organic ether solvent and the mass ratio of the small organic molecule additive to the inorganic sodium salt additive, the electrochemical performance and the thermal stability of the battery are improved.

The invention provides a method of reducing dinitrogen to produce ammonia, the method comprising: contacting a cathode of an electrochemical cell with an electrolyte comprising: (i) a metal cation selected from the group consisting of lithium, magnesium, calcium, strontium, barium, zinc, aluminium, vanadium and combinations thereof, wherein the metal cation is present at a concentration of greater than 0.5 mol / L in the electrolyte, (ii) one or more anions comprising at least one negative ion selected from the group consisting of fluorinated sulfonyl imides, fluorinated sulfonyl methides and combinations thereof, (iii) a proton carrier; and (iv) optionally, at least one phosphonium cation, wherein the combined amount of the metal cation and the optional at least one phosphonium cation is greater than 1 mol / L in the electrolyte; supplying dinitrogen to the electrochemical cell for cathodic reduction; and applying a potential at the cathode sufficient to reduce the dinitrogen, thereby producing ammonia.

Mcl-1 selective inhibitors, Bcl-2 selective inhibitors, and Mcl-1 / Bcl-2 dual inhibitors and methods of using the same for the treatment of disease are disclosed.

An endocyclic thiamidoamide-arylamide compound and a pharmaceutical composition comprising said compound are described, as well as the use of the same or of the pharmaceutical composition in the treatment of hepatitis B. In particular, a compound that can be used as an inhibitor of HBV replication and that has the structure shown in chemical formula (L), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, is described.

The invention belongs to the field of organic synthesis, and relates to a method for synthesizing beta-sulfamide. According to the method, primary amine and alkenyl sulfonyl fluoride are used as raw materials, silica gel is used as a catalyst, and a reaction is carried out in a solvent to generate the beta-sulfamide compound. Compared with a traditional method for synthesizing beta-sulfamide through a multi-step reaction, the beta-sulfamide synthesis method is easy and convenient to operate, mild in condition, low in reagent cost, easy to obtain, high in reaction yield and wide in substrate application range. The invention also discloses an application of beta-sulfamide compounds synthesized from primary amine and alkenyl sulfonyl fluoride under a silica gel catalysis condition in drug modification.

The invention discloses a pyrimidine derivative containing a thiosemicarbazide structure and application of the pyrimidine derivative, and relates to the technical field of medicines, the compound has good oxidation resistance and alpha-glucosidase resistance activity, and the compound is 2-(4, 4 '-difluorophenyl)-2-(4, 4'-difluorophenyl)-2-(4, 4 '-difluorophenyl)-2-(4, 4' The IC50 values of the compound 2-(4, 6-dimethyl pyrimidine-2-yl)-N-methylhydrazine-1-methylsulfamide on DPPH (1, 1-diphenyl-2-picrylhydrazyl) scavenging activity and ABTS (2, 2, 6-dimethyl pyrimidine-2-yl)-N-methylhydrazine-1-methylsulfamide are 3.96 mu g / mL and 2.01 mu g / mL respectively, the IC50 value of the compound 2-(4, 6-dimethyl pyrimidine-2-yl)-N-methylhydrazine-1-methylsulfamide on alpha-glucosidase inhibitory activity is 38.62 mu g / mL, the effect is best, and the compound 2-(4, 6-dimethyl pyrimidine-2-yl)-N-methylhydrazine-1 The pyrimidine derivative containing the thiosemicarbazide structure has a general formula shown in the specification, and is superior to control medicaments such as vitamin C, vitamin E and acarbose.

The invention discloses an industrial production method of a quinoline mercaptoacetic acid sulfonamide compound, which comprises the following steps: carrying out condensation reaction on an intermediate D-3 and methyl sulfonamide under the action of a condensing agent, concentrating under reduced pressure until no liquid flows out after the reaction is finished, adding acid, separating out a large amount of solid, filtering, pulping a filter cake with purified water, filtering and drying to obtain the quinoline mercaptoacetic acid sulfonamide compound. A compound D is obtained. The problems that in the prior art, the reaction yield is low, starting material impurities are contained, and the process is complex are solved, and the prepared compound D is low in cost, simple in process operation, high in yield, stable in quality and suitable for large-scale industrial production.

This invention discloses 2'-hydroxy-4,4',6'-trimethoxychalcone and 5,7,4'-trimethoxyflavanone sulfonamide derivatives, their synthesis methods and applications, belonging to the field of pharmaceutical technology, and involving two series of compounds: 3-sulfonamido-2'-hydroxy-4,4',6'-trimethoxychalcone and 8,3'-disulfonamido-5,7,4'-trimethoxyflavanone, and their preparation methods. Starting with 2-hydroxy-4,6-dimethoxyacetophenone and p-anisaldehyde or 4-methoxy-3-nitrobenzaldehyde, 2'-hydroxy-4,4',6'-trimethoxychalcone or 3-amino-2'-hydroxy-4,4',6'-trimethoxychalcone intermediates were synthesized via the Claisen-Schmidt reaction. Then, through sulfonation and intramolecular Michael addition reactions, 2'-hydroxy-4,4',6'-trimethoxychalcone and 5,7,4'-trimethoxyflavanone sulfonamide derivatives were synthesized. The preparation method is simple, mild, and yields high results. In vitro and in vivo activity tests show that the derivatives disclosed in this invention have significant in vitro inhibitory activity against gastric cancer, esophageal cancer, colorectal cancer, and lung cancer cell lines, acting as inhibitors of the protein YBX1 / RPN1. Clinically, they can be applied to targeted therapy for cancers such as gastric cancer, esophageal cancer, colorectal cancer, and lung cancer.

The invention relates to an internal sulfonamide compound and a preparation method thereof. The invention relates to a preparation method of a sulfamide compound, which comprises the following steps: mixing an aminomalonic acid diethyl ester compound or an N-benzyl malonic acid monomethyl ester monoamide compound, a beta-aryl vinyl sulfonyl fluoride compound and MS, adding a solvent and a base catalyst, reacting at room temperature for 12-24 hours, separating and purifying to obtain the amide compound. The sulfamide compound and the preparation method thereof have the advantages of being simple in method, free of transition metal catalysis, wide in substrate range, mild in reaction condition, good in universality and the like.

Disclosed is a pharmaceutical composition for treatment of Parkinson's disease comprising N-[(1S)-2,2,5,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide represented by formula (1) or a pharmaceutically acceptable salt thereof.

The present invention discloses a sulfur-containing amide type organic molybdenum compound and its preparation method and application, which belongs to the technical field of lubricating additives. The structural formula is as follows: #imgabs0# wherein R1 is a C2-C3 straight chain or branched alkyl group, R2 is a C8-C 26 Straight-chain or branched alkyl; a sulfur-amide-type organic molybdenum compound prepared by the present invention can be used as a lubricating grease additive, has good tribological properties, and can significantly improve the friction-reducing and anti-wear properties of lubricating grease.

The application provides a preparation method of a pyrimidine sulfamide compound, and the method overcomes the defects of the prior art, such as the need of using an excessive strong base, low conversion efficiency, and more by-products, and the like, and the method is characterized in that the pyrimidine sulfamide is generated through the reaction of the combined action of a molecular sieve and a catalyst, the reaction condition is mild, the step is economical, the environment is friendly, the comprehensive production cost is low, the raw material is easy to obtain, the environment is friendly and economical, and the method is beneficial to the industrialized production of the pyrimidine sulfamide compound.

The invention relates to application of a sulfonamide compound or a pharmaceutical composition containing the sulfonamide compound in preparation of a medicine for treating pulmonary edema. The medicine has a prominent curative effect on pulmonary edema by inhibiting NKCC1 targets of lungs and is high in safety, so that adverse effects such as electrolyte disorder caused by potent diuretics are reduced, and the medicine is a better new medicine for clinically treating pulmonary edema.

The invention discloses a modified nylon composite flame retardant and a preparation method thereof, and the preparation method comprises the following steps: mixing agmatine and sulfuric acid according to a ratio of 1: 1, adding ethanol, heating and stirring, and carrying out rotary evaporation to remove a solvent to obtain agmatine sulfate; then, 4, 4 '-diaminodiphenyl sulfone and phenylphosphoryl dichloride are dissolved in acetonitrile, and after a reaction, a phosphorus-sulfur composite flame retardant is obtained; then mixing brominated polystyrene and antimony trioxide according to a ratio of 3: 1, adding a dimethyl sulfoxide solvent, and stirring to obtain a bromine-antimony composite flame retardant; and finally, mixing all the components with the long glass fiber, performing high-speed stirring and twin-screw extrusion melt blending, and performing cooling and pelletizing molding. The agmatine sulfate can provide gas-phase flame retardance, the phosphorus-sulfur composite flame retardant generates a carbon layer to enhance solid-phase flame retardance, and the bromine-antimony composite flame retardant synergistically delays flame propagation, so that the flame retardance stability and durability of the nylon composite flame retardant are improved, and the long-term use safety in a high-temperature environment is ensured.

The invention discloses a low-dielectric-loss chemical silver plating solution and a preparation method thereof. Each liter of the chemical silver plating solution comprises the following components: 0.2-10 g of soluble silver salt, 15-35 g of a complexing agent, 0.1-2 g of soluble nickel salt, 5-25 g of a reducing agent, 0.5-3 g of a stabilizer, 0.5-3 g of a brightener and the balance of water and a pH regulator. The complexing agent comprises at least one of carboxyl polyethylene glycol sulfamide and sodium 2, 3-dimercaptopropanesulfonate. The pH value of the prepared low-dielectric-loss chemical silver plating solution is weak acidity, the low-dielectric-loss chemical silver plating solution is good in compatibility and high in stability, very high stability can be kept after multi-period plating, and meanwhile a prepared silver plating layer is flat and uniform, has good thickness and white and bright metal luster and has high hardness and good wear resistance.

The application discloses a sulfonamide compound, a preparation method and application thereof. The compound can selectively antagonize a human and mouse NOD1 signal path, can inhibit secretion of inflammatory cytokines, and can be used for treating inflammatory diseases, in particular, gastritis caused by helicobacter pylori infection.

The present invention concerns the compound aprocitentan, {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide:and its use as endothelin receptor antagonist, in combination with an SGLT-2 inhibitor. The invention further relates to pharmaceutical compositions comprising aprocitentan in combination with said SGLT-2 inhibitor. The invention further relates to such pharmaceutical compositions comprising crystalline forms of aprocitentan.

The present invention provides novel fluorinated cyclic derivatives of sulfonamides and sulfones useful in the treatment of various diseases and disorders associated with TRPML activity, such as neurodegenerative diseases, lysosomal storage diseases, muscular dystrophy, age-related common neurodegenerative diseases, oxidative stress or reactive oxygen substance (ROS)-related diseases, aging, etc. The invention also relates to a composition, a preparation method and application thereof.

The application belongs to the field of carbon dioxide photocatalytic materials, and relates to a spin catalytic material for promoting CO2 photocatalysis and a preparation method thereof. The material is a high-activity metal grid supramolecule obtained by a volatilization method from a ligand 2,2'-pyrazine dihydrazine methanesulfamide (pbd) and a metal salt. As a photocatalyst, the material can adjust multiple spin states on a single Fe site in the metal grid supramolecule to effectively promote a visible light driven CO2 reduction reaction (CO2RR). After 1h of irradiation, the CO2 to CO yield can reach 6.26mmol g ‑1 , which shows an effective strategy of designing spin-based photocatalysts through supramolecular assembly to promote artificial photosynthesis.

The application discloses a 1, 2, 3-triazole sulfamide derivative, a preparation method and application thereof. The compound has a general formula (A). The synthesis method is as follows: sulfamide is used as a starting material, diazotization, azidation, and then coupling with ethyl acetoacetate to complete the docking of the triazole ring and the sulfamide, and an amide bond is introduced into the structure, and then a series of novel 1, 2, 3-triazole sulfamide derivatives are synthesized. The compounds have excellent bacteriostatic, insecticidal and fungicidal functions on escherichia coli, pseudomonas aeruginosa, salmonella typhi, staphylococcus aureus, bacillus subtilis, and fungi such as candida albicans and aspergillus niger, pests and plant pathogenic bacteria in forestry and other fields.

The invention belongs to the field of medical chemistry, and relates to a pharmaceutical composition of an internal sulfonamide compound, in particular to a pharmaceutical composition of a compound shown as a formula I or pharmaceutically acceptable salt thereof and medical application of the pharmaceutical composition. # imgabs0 #

The invention belongs to the technical field of fracturing, and particularly relates to a temperature-resistant thickening agent for fracturing, and a preparation method of the temperature-resistant thickening agent comprises the following steps: modifying an aromatic ring on the surface of bentonite by using an aromatic ring silane coupling agent, reacting with chlorosulfonic acid to form a sulfonic acid group, and finally modifying a sulfonyl chloride group on the bentonite under the action of a chlorinating agent and a catalyst. Secondly, guar gum is modified with amino through an amino silane coupling agent, then under the catalytic action of triethylamine, the amino-modified guar gum and sulfonyl chloride groups on the modified bentonite are subjected to a nucleophilic substitution reaction to generate sulfonamide groups, and the modified guar gum / bentonite compound, namely the temperature-resistant thickening agent, is better in temperature resistance, salt resistance and anti-shearing effect, and can be used for preparing the high-temperature-resistant thickening agent. And the device can be suitable for more fracturing construction sites.

The present invention concerns novel crystalline forms of {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide, processes for the preparation thereof, pharmaceutical compositions comprising said crystalline forms, pharmaceutical compositions prepared from such crystalline forms, and their use as endothelin receptor antagonists. It also relates to new uses of {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide, either alone or in combination with other active ingredients or therapeutic agents.

Provided herein are combinations of a methionine adenylyltransferase II alpha (MAT2A) inhibitor and a topoisomerase inhibitor, splicing inhibitor sulfonamide, or a KIF18 inhibitor. Also provided are methods of using such combinations to treat diseases or conditions, such as cancer.

The invention discloses a macromolecule capable of promoting intake of anticancer drugs, a composition and application of the macromolecule in preparation of the anticancer drugs. The macromolecule contains a plurality of guanidino groups and a plurality of sulfamide groups, the macromolecule has the average molecular weight smaller than or equal to 50,000 Da, and the zeta potential of the macromolecule is smaller than or equal to + 2 mV under the simulated normal physiological condition (pH 7.4) and larger than or equal to + 5 mV under the simulated tumor subacid environment (pH 6.5-6.8). The macromolecules can promote the aggregation and permeation of the anticancer drugs in tumor tissues and promote the anticancer drugs to enter cancer cells, and the anticancer effect of the anticancer drugs can be improved when the macromolecules are combined with the anticancer drugs, so that the anticancer effect is remarkably improved when the macromolecules are combined with the anticancer drugs under the same dosage of the anticancer drugs, and the anticancer effect of the anticancer drugs is improved. Or the toxic and side effects of the anticancer drugs are greatly reduced by combining with the macromolecules under the condition of lower dosage of the anticancer drugs.

The invention relates to an exhaled air condensate metabolite composition, a kit and a method for predicting the risk of lung cancer. The exhaled air condensate metabolite composition for predicting the risk of the lung cancer comprises piperic acid, ethionamide, ethyl salicylate, hydroxy fatty acid branched chain fatty acid ester (2: 0 / 24: 4) (hereinafter abbreviated as FAHFA (2: 0 / 24: 4), glycine, indole-3-butyric acid, 4-hydroxyquinoline and methoxy indoleacetic acid. The kit for predicting the risk of the lung cancer comprises reagents required for detecting the contents of piperic acid, ethionamide, ethyl salicylate, FAHFA (2: 0 / 24: 4), glycine, indole-3-butyric acid, 4-hydroxyquinoline and methoxy indoleacetic acid in an exhaled gas condensate sample extraction solution. By means of the combined marker, a good prediction effect on the risk of the lung cancer can be achieved.